-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

Benzinga·08/10/2026 17:17:38
Listen to the news
B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.